Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 15/20 | 0.74 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | DRD1 | P21728 | 1/20 | 0.53 |
| ▸ | DRD5 | P21918 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.50 |
| ▸ | CDK4 | P11802 | 1/20 | 0.49 |
| ▸ | CCND1 | P24385 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6474123 | 0.87 | TRPV1 (0.69) | TRPV1CDK4CCND1 | |
| SCHEMBL6483821 | 0.87 | BAZ2B (0.62) | TRPV1CDK4CCND1 | |
| SCHEMBL6474459 | 0.87 | BAZ2B (0.62) | TRPV1CDK4CCND1 | |
| SCHEMBL6485981 | 0.87 | BAZ2B (0.62) | TRPV1CDK4CCND1 | |
| SCHEMBL6492381 | 0.86 | CDK4 (0.63) | TRPV1CDK4CCND1 | |
| SCHEMBL7042654 | 0.84 | BAZ2B (0.65) | TRPV1DRD2DRD1DRD5DRD3 | |
| SCHEMBL6482962 | 0.84 | TRPV1 (0.54) | TRPV1CDK4CCND1 | |
| SCHEMBL6483852 | 0.83 | TRPV1 (0.53) | TRPV1CDK4CCND1 | |
| SCHEMBL6038224 | 0.83 | HTR6 (0.54) | TRPV1DRD2CDK4CCND1 | |
| SCHEMBL6482605 | 0.80 | CDK4 (0.63) | TRPV1CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030216378-A1 | Azepino[4,5-b]pyrano[3,2-e]indoles | PHARMACIA & UPJOHN CO. | 2003-11-20 | — | — | US | disclosed |
| EP-1296988-A1 | AZEPINO 4,5-B]PYRANO 3,2-E]INDOLES | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-02 | — | — | EP | disclosed |
| US-6503899-B2 | Administering to the patient sufffering from anxiety, obesity, depression or stress related diseases an Azepino(4,5-b)pyrano(3,2-e)indoles | PHARMACIA & UPJOHN COMPANY | 2003-01-07 | — | — | US | disclosed |
| US-20020022616-A1 | Azepino[4,5-b]pyrano[3,2-e]indoles | PHARMACIA & UPJOHN COMPANY | 2002-02-21 | — | — | US | disclosed |
| WO-2002004457-A1 | AZEPINO[4,5-B]PYRANO[3,2-E]INDOLES | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2002004456-A1 | SUBSTITUTED 2,3,7,8,9,10,11,12-OCTAHYDROAZEPINO[4,5-b]PYRANO[3,2-e]INDOLES | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216378-A1 | Azepino[4,5-b]pyrano[3,2-e]indoles | NPY5R, HTR5A, IDO1 | TRPV1 1346/4885DRD2 369/4885DRD1 211/4885 |
| US-20020022616-A1 | Azepino[4,5-b]pyrano[3,2-e]indoles | NPY5R, HTR3C, HTR5A | TRPV1 1055/4885DRD2 205/4885DRD1 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.